IDEAYA Biosciences Announces ASCO 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
- Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT
- The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET
- 定於 2024 年 6 月 3 日星期一中部夏令時間上午 9:51 在 ASCO 2024 上進行口頭演講
- 摘要摘要將於美國東部時間 2024 年 5 月 23 日星期四下午 5:00 左右公佈
SOUTH SAN FRANCISCO, Calif., April 24, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that interim results from the investigator-sponsored Phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant/adjuvant treatment in uveal melanoma (UM) have been selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.
加利福尼亞州南舊金山,2024年4月24日 /PRNewswire/ — 致力於發現和開發靶向療法的精準醫學腫瘤學公司IDEAYA Biosciences, Inc.(納斯達克股票代碼:IDYA)今天宣佈,由研究者贊助的評估darovasertib作爲葡萄膜黑色素瘤(UM)新輔助/輔助治療的安全性和有效性的2期試驗的中期結果是入選2024年5月31日至6月4日在伊利諾伊州芝加哥舉行的2024年美國臨床腫瘤學會(ASCO)年會上作口頭演講。
Details for the oral presentation are as follows:
口頭陳述的詳情如下:
Session: Melanoma/ Skin Cancers
會話: 黑色素瘤/皮膚癌
Title: A Phase 2 Safety and Efficacy Study of Neoadjuvant/Adjuvant Darovasertib for Localized Ocular Melanoma
標題: 新輔助/輔助Darovasertib治療局部眼部黑色素瘤的2期安全性和有效性研究
Presenter: Anthony Joshua, M.B.B.S, Ph.D., FRACP
演示者: 安東尼·約書亞,工商管理學學士、博士,FRACP
Abstract number: 9510
摘要編號: 9510
Date and Time: June 3, 2024, at 9:51 AM CDT
日期和時間: 2024 年 6 月 3 日,中部夏令時間上午 9:51
ASCO will publish the abstract summary on Thursday, May 23, 2024, at approximately 5:00 pm ET.
ASCO將於美國東部時間2024年5月23日星期四下午5點左右發佈摘要摘要。
譯文內容由第三人軟體翻譯。